Table 2 Clinical characteristics of COVID-19 patients with or without elevated TnI (TnT)
Source | Severe disease/ARDS | ICU | Death | NT-proBNP, Median (IQR), pg/mL | Definition of cardiac injury | ||||
|---|---|---|---|---|---|---|---|---|---|
Elevated TnI/TnT, N/total | Non-elevated TnI/TnT, N/total | Elevated TnI/TnT, N/total | Non-elevated TnI/TnT, N/total | Elevated TnI/TnT, N/total | Non-elevated TnI/TnT, N/total | Elevated TnI/TnT | Non-elevated TnI/TnT | ||
Liu et al. [30] | 11/15 | 18/276 | 11/15 | 15/276 | 1/15 | 0/276 | NA | NA | TnI > 0.03 μg/L |
Xu et al. [28] | 6/6 | 13/47 | 6/6 | 2/47 | 3/6 | 0/47 | NA | NA | TnT-HSST > 28 pg/ml |
Wu et al. (b) [27] | NA | NA | 27/62 | 23/126 | 31/62 | 12/126 | NA | NA | Hs-TnI ≥ 6.126 pg/mL |
Hui et al. [22] | 4/4 | 1/16 | NA | NA | NA | NA | NA | NA | NA |
Wang et al. [16] | NA | NA | 8/10 | 28/128 | NA | NA | NA | NA | NA |
Yang et al. [18] | NA | NA | NA | NA | 9/12 | 23/40 | NA | NA | Hs-TNI > 28 pg/mL |
Shi et al. [4] | 48/82 | 49/334 | NA | NA | 42/82 | 15/334 | 1689 (698–3327) | 139 (51–335) | Hs-TnI > 0.04 ng/mL |
Chen et al. [35] | NA | NA | NA | NA | 68/83 | 26/120 | NA | NA | Hs-TnI > 15.6 pg/mL |
Guo et al. [36] | NA | NA | NA | NA | 31/52 | 12/135 | 817.4 (336.0–1944.0) | 141.4 (39.3–303.6) | Elevated TnT levels |